Drug Resistant EpilepsyNCT07546253
Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy
An observational study of Drug Resistant Epilepsy and Refractory Epilepsy, run by NeuroOne Medical Technologies Corporation at 3 sites in United States.
Trial summary
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Drug Resistant Epilepsy, Refractory Epilepsy
- What is being tested?
- Participants are not assigned an intervention as part of the study.
- How many people
- 100 participants
- Where
- 3 sitesUnited States
- Study dates
- 18 Sep 2026to Jul 2028
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients diagnosed with drug resistant epilepsy (DRE)
Who may be able to join
- Patients diagnosed with drug resistant epilepsy (DRE)
- Patients who have received or will receive EVO® sEEG-RF implants
- Patients who have undergone or may undergo an RF ablation procedure using the OneRF Ablation System.
- Patient, or legal guardian, understands study procedures and voluntarily signs informed consent in accordance with institutional policies. In the event that the patient is under the age of 18, the patient may also be required (per IRB) to sign an assent affirming their agreement to participate.
Who cannot join
- 1. Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Recruiting
Cooperman Barnabas Medical Center - 94 Old Short Hills Rd
Livingston, New Jersey, 07039
Robert E Gross, MD, PhD, 833-656-3876, rg1246@rutgers.edu
Robert E Gross, MD, PhD
- Recruiting
Nicklaus Children's Hospital
Miami, Florida, 33155
Robert Buckley, MD, 206-272-0879, robert.buckley@nicklaushealth.org
Robert Buckley, MD
- Recruiting
Robert Wood Johnson University Hospital - 1 Robert Wood Johnson Pl
New Brunswick, New Jersey, 08901
Robert E Gross, MD, PhD, 833-656-3876, rg1246@rwjms.rutgers.edu
Robert E Gross, MD, PhD
About this study
Official title: OneRF® Ablation System Post-Market Real-World Evidence Registry
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.
Read the detailed description
Stereoelectroencephalography (SEEG) -guided radiofrequency (RF) ablation is a minimally invasive procedure that uses thin electrodes already placed in the brain for seizure diagnosis to deliver targeted heat to destroy brain tissue associated with epileptic seizures.
The OneRF Ablation System is a device cleared by the FDA in 2023 for this treatment. Since receiving FDA clearance, the OneRF Ablation System has been used in ablation procedures in patients with seizures at multiple hospitals. Early published clinical data show a meaningful decrease in seizure burden (1). One of the key features of the device is the ability to monitor and control temperature throughout the treatment. While the advantages of real-time temperature monitoring and control are increasingly being recognized, additional clinical information would be beneficial to understand the full impact of this technology on patient outcomes.
This study is a prospective and retrospective, multicenter, observational registry. The study will take place at up to 10 sites across the United States and is expected to enroll up to 100 participants, including both adults and children. The goal of the registry is to evaluate clinical outcomes and device performance of the OneRF Ablation System.
The study will include data collection from patients with drug resistant epilepsy who are undergoing sEEG evaluation for seizure diagnosis and treatment, and:
- Have already had an ablation procedure with the OneRF Ablation System, or
- Are being considered for treatment with the OneRF Ablation System as part of their clinical seizure evaluation.
Data will be collected from patients before and throughout routine follow-up visits for up to one year after the RF ablation procedure. The study will look at seizure control, quality of life, adverse events, how the procedure is performed, and factors that may predict which patients benefit most.
Taking part in this registry does not change a patient's medical care. The study only collects information from treatments and follow-up visits that are already part of routine practice care for seizure management.
- Conditions
- Drug Resistant Epilepsy, Refractory Epilepsy
- Being tested
- Participants are not assigned an intervention as part of the study.
- Keywords
- radiofrequency ablation, sEEG, epilepsy
- Medical subject headings
- Drug Resistant Epilepsy, Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Participants are not assigned an intervention as part of the study.Other
For observational studies, participants are not assigned an intervention as part of the study.
| Study group | Role | What they receive |
|---|---|---|
| Patients who have received or will receive an RF ablation procedure using the OneRF Ablation System | This registry collects both retrospective data from patients diagnosed with drug resistant epilepsy (DRE) who previously underwent a RF ablation procedure and prospective data from DRE patients who are considered for a RF ablation procedure using the OneRF Ablation System. Receives: Other: Participants are not assigned an intervention as part of the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate seizure outcomes
Percentage of seizure-free patients and responders (seizure reduction >50%) at longitudinal time points
Measured: baseline to up to one (1) year
Evaluate changes in seizure frequency
Change is seizure frequency at longitudinal time points
Measured: baseline to up to one (1) year
Evaluate changes in seizure severity
Change is seizure severity at longitudinal time points
Measured: baseline to up to one (1) year
Evaluate antiseizure medication
Changes in the antiseizure medication (ASM) dosage
Measured: baseline to up to one (1) year
Gather product deficiency and patient safety events
Number and description of adverse events related to the device, user, RF ablation procedure, therapy, and others
Measured: From enrollment through the completion of follow-up visits (approximately a one-year period)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study start18 Sep 2026
- Primary completionJul 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Drug Resistant EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- NeuroOne Medical Technologies Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07546253
- Sponsor's protocol ID
- N1-OneRF-Registry-01
- Status last verified
- Oct 2026
- First submitted
- 6 Apr 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Freund BE, Vijayanarasimhan V, Safa A, Ekert J, Colella FE, Block C, Sabsevitz D, Perez-Vega C, Middlebrooks EH, Mirsattari SM, Byrne R, Tatum WO. Stereo-electroencephalography-guided radiofrequency thermocoagulation in patients with implanted neuromodulation devices: patient series. J Neurosurg Case Lessons. 2026 Aug 3;12(5):CASE26376. doi: 10.3171/CASE26376. Print 2026 Aug 3.
PubMed 42546343Zavala B, Kondylis E, Bulacio J, Chisholm J, Harasimchuk S, Rammo R, Bingaman W, Serletis D. Initial Clinical Experience with the First FDA-Approved sEEG-Guided Radiofrequency Ablation System Featuring Real-Time Temperature Monitoring: A Case Series. Stereotact Funct Neurosurg. 2026 Mar 5:1-8. doi: 10.1159/000551390. Online ahead of print.
PubMed 41785222
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OneRF® Ablation System Post-Market Real-World Evidence Registry
- ClinicalTrials.gov ID
- NCT07546253
- Acronym / sponsor ID
- N1-OneRF-Registry-01
- Conditions
- Drug Resistant Epilepsy, Refractory Epilepsy
- Keywords
- radiofrequency ablation, sEEG, epilepsy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- NeuroOne Medical Technologies CorporationIndustry (pharma, biotech, devices)
- Collaborators
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- Study start
- 18 Sep 2026 (actual)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.
Detailed description
Stereoelectroencephalography (SEEG) -guided radiofrequency (RF) ablation is a minimally invasive procedure that uses thin electrodes already placed in the brain for seizure diagnosis to deliver targeted heat to destroy brain tissue associated with epileptic seizures.
The OneRF Ablation System is a device cleared by the FDA in 2023 for this treatment. Since receiving FDA clearance, the OneRF Ablation System has been used in ablation procedures in patients with seizures at multiple hospitals. Early published clinical data show a meaningful decrease in seizure burden (1). One of the key features of the device is the ability to monitor and control temperature throughout the treatment. While the advantages of real-time temperature monitoring and control are increasingly being recognized, additional clinical information would be beneficial to understand the full impact of this technology on patient outcomes.
This study is a prospective and retrospective, multicenter, observational registry. The study will take place at up to 10 sites across the United States and is expected to enroll up to 100 participants, including both adults and children. The goal of the registry is to evaluate clinical outcomes and device performance of the OneRF Ablation System.
The study will include data collection from patients with drug resistant epilepsy who are undergoing sEEG evaluation for seizure diagnosis and treatment, and:
- Have already had an ablation procedure with the OneRF Ablation System, or
- Are being considered for treatment with the OneRF Ablation System as part of their clinical seizure evaluation.
Data will be collected from patients before and throughout routine follow-up visits for up to one year after the RF ablation procedure. The study will look at seizure control, quality of life, adverse events, how the procedure is performed, and factors that may predict which patients benefit most.
Taking part in this registry does not change a patient's medical care. The study only collects information from treatments and follow-up visits that are already part of routine practice care for seizure management.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients who have received or will receive an RF ablation procedure using the OneRF Ablation System | – | Other: Participants are not assigned an intervention as part of the study.This registry collects both retrospective data from patients diagnosed with drug resistant epilepsy (DRE) who previously underwent a RF ablation procedure and prospective data from DRE patients who are considered for a RF ablation procedure using the OneRF Ablation System. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients diagnosed with drug resistant epilepsy (DRE)
Key inclusion criteria (4 listed)
- Patients diagnosed with drug resistant epilepsy (DRE)
- Patients who have received or will receive EVO® sEEG-RF implants
- Patients who have undergone or may undergo an RF ablation procedure using the OneRF Ablation System.
- Patient, or legal guardian, understands study procedures and voluntarily signs informed consent in accordance with institutional policies. In the event that the patient is under the age of 18, the patient may also be required (per IRB) to sign an assent affirming their agreement to participate.
Key exclusion criteria (1 listed)
- 1. Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Participants are not assigned an intervention as part of the study.For observational studies, participants are not assigned an intervention as part of the study. | Other | Patients who have received or will receive an RF ablation procedure using the OneRF Ablation System |
Primary outcome
Evaluate seizure outcomes
Time frame: baseline to up to one (1) year
Percentage of seizure-free patients and responders (seizure reduction >50%) at longitudinal time points
Evaluate changes in seizure frequency
Time frame: baseline to up to one (1) year
Change is seizure frequency at longitudinal time points
Evaluate changes in seizure severity
Time frame: baseline to up to one (1) year
Change is seizure severity at longitudinal time points
Evaluate antiseizure medication
Time frame: baseline to up to one (1) year
Changes in the antiseizure medication (ASM) dosage
Gather product deficiency and patient safety events
Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)
Number and description of adverse events related to the device, user, RF ablation procedure, therapy, and others
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Background: PubMed 42546343Freund BE, Vijayanarasimhan V, Safa A, Ekert J, Colella FE, Block C, Sabsevitz D, Perez-Vega C, Middlebrooks EH, Mirsattari SM, Byrne R, Tatum WO. Stereo-electroencephalography-guided radiofrequency thermocoagulation in patients with implanted neuromodulation devices: patient series. J Neurosurg Case Lessons. 2026 Aug 3;12(5):CASE26376. doi: 10.3171/CASE26376. Print 2026 Aug 3.
- Background: PubMed 41785222Zavala B, Kondylis E, Bulacio J, Chisholm J, Harasimchuk S, Rammo R, Bingaman W, Serletis D. Initial Clinical Experience with the First FDA-Approved sEEG-Guided Radiofrequency Ablation System Featuring Real-Time Temperature Monitoring: A Case Series. Stereotact Funct Neurosurg. 2026 Mar 5:1-8. doi: 10.1159/000551390. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Drug Resistant Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
Recruiting
Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Refractory Epilepsy
RecruitingPhase 1
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Epilepsy
Not yet recruiting
Electrophysiological Dose-Response to Anterior Thalamic Deep Brain Stimulation in Drug-Resistant Focal Epilepsy
Drug Resistant Epilepsy, Focal Epilepsy
Recruiting
Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Refractory Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Drug Resistant Epilepsy and Refractory Epilepsy, run by NeuroOne Medical Technologies Corporation at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aura Kullmann, PhD (4123393027, aurak@nmtc1.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate seizure outcomes (time frame: baseline to up to one (1) year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07546253, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.